Venture capital spending to keep cooling in ’23 amid economic concerns
By Mike Harris, Special to the Business Times This year will be a cautious one for venture capital investors, panelists at a round table discussion in Westlake Village said on Jan. 18. “I think it will be slow and cautious,” said moderator Scott Alderton, managing partner of Los Angeles-based law firm Stubbs, Alderton and Markiles, Read More →
A fresh face: Avenir, formerly CURE, embraces rebrand
In a continued effort to rebuild its image and set a new standard for the company, CURE Pharmaceutical has rebranded to Avenir Wellness, the company announced on Jan. 17. Formerly located in Oxnard, Avenir’s new headquarters is now in Sherman Oaks, as the company’s decision to rebrand is also the result of its selling of Read More →
Barsky becomes first female athletic director in UCSB history
Kelly Barsky always dreamed of growing up to be an educator. In 2023, she’s not only that but so much more — a true inspiration for women in the world of sports. On Jan. 3, UC Santa Barbara made a historic hire, naming Barsky as the new director of athletics, and in doing so, becoming Read More →
Health Forecast: ‘Tripledemic’ a real concern to start 2023
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Capsida announces multi-year agreement with Eli Lilly subsidiary
Thousand Oaks-based Capsida Therapeutics has entered into a multi-year agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, to develop transformative genetic medicines for serious diseases, Capisda announced Jan. 4. As per the agreement, Capsida will receive $55 million in the form of an upfront payment and a commitment to participate Read More →
Striking up a new note
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dantari raises $47M to target cancers and rare diseases
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
